TY - JOUR
T1 - The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C
AU - Kainuma, Mosaburo
AU - Hayashi, Jun
AU - Sakai, Shinya
AU - Imai, Kazuaki
AU - Mantani, Naoki
AU - Kohta, Kazufumi
AU - Mitsuma, Tadamichi
AU - Shimada, Yutaka
AU - Kashiwagi, Seizaburo
AU - Terasawa, Katsutoshi
PY - 2002
Y1 - 2002
N2 - The purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-β and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-β alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1 b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.
AB - The purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-β and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-β alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1 b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.
KW - Adverse Effects
KW - Dai-seiryu-to
KW - IFN-β
KW - Mao-to
UR - http://www.scopus.com/inward/record.url?scp=1042309282&partnerID=8YFLogxK
U2 - 10.1142/S0192415X02000284
DO - 10.1142/S0192415X02000284
M3 - 学術論文
C2 - 12230024
AN - SCOPUS:1042309282
SN - 0192-415X
VL - 30
SP - 355
EP - 367
JO - American Journal of Chinese Medicine
JF - American Journal of Chinese Medicine
IS - 2-3
ER -
